KX-826 failed Phase III trials due to high placeboeffects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
Dutasteride is unlikely to worsen hair loss; shedding is often temporary. Other factors like inconsistent use, placeboeffect, or additional treatments may influence perceived results.
Exercise may be improving hair thickness and reducing thinning for a 50-year-old man using topical finasteride, minoxidil, Nizoral, and microneedling. The improvement could be due to exercise, the treatments, or a placeboeffect.
Potential side effects of 5AR inhibitors like finasteride and dutasteride. Users debate risks, benefits, and personal experiences with these hair loss treatments.